Reactive oxygen species (ROS) (e.g. superoxide anion (O2 -)) are known to be involved in many diseases and disorders including hypertension and ischemia which are known as ROS related diseases.
Serum lipid peroxides or ROS are increased in essential hypertensive patients or hypertensive animal models. 1 Several studies have focused on XO as a source of oxidative stress. Xanthine oxidase (XO) plays important role in excessive generation of ROS especially superoxide anion (O2 -). XO is known to exist initially as xanthine dehydrogenase in many tissues, it is converted to XO. Its activity being highly upregulated in various pathological conditions, which becomes a major source of (O2 -). As a consequence, (O2 -) generation by XO is regarded as an etiological mechanism of such diseases, and thus it is considered as a therapeutic target for these ROS related diseases 2 .
Xanthine oxidoreductase, when transferred into its oxidase form xanthine oxidase (XO), generates super-oxide and hydrogen peroxide upon conversion of xanthine to uric acid. Vascular and myocytelocalized XO is increased in coronary artery disease, and circulating XO levels are upregulated in congestive heart failure. 3 Growing evidence supports the role of uric acid as a biomarker of oxidative stress and as a mediator of hypertension. 4 Several evidences have been shown positive relationship between serum uric acid (UA) levels and cardiovascular mortality in patients with chronic kidney disease. The reduction in serum UA levels by administering the xanthine oxidase (XO) inhibitor allopurinol has been shown to slow the progression of renal dysfunction and decrease the risk of cardiovascular disease. This beneficial effect is thought to originate from a lowering of the plasma UA level, because UA itself has been shown to generate oxidative stress in adipocytes, vascular endothelial cells, and vascular smooth muscle cells.
XO inhibition in hyperuricemic with dilated and ischemic cardiomyopathy leads to an improvement of vascular Nitric Oxide (NO) bioavailability 5 , and local infusion of allopurinol into the coronary circulation in patients with dilated cardiomyopathy lowered myocardial oxygen consumption. 6 Allopurinol is a potent xanthine oxidase inhibitor that is used in hyperuricemic patients to prevent gout. It has also been shown to decrease cardiovascular complications and to reduce blood pressure in hypertensive patients. 7 Harrison et al. 8 have found that angiotensin II (AII) administration markedly increases ROS. This effect is suppressed by AII receptor antagonists. These findings strongly suggest that ROS are involved in AII-induced blood pressure elevation or vascular damage. 9 Angiotensin II-induced endothelial dysfunction also shows the significant role of XO in oxidative injury.
Endothelium preserves its integrity through endothelium-relaxing dependent factor, which is the best to be characterized as NO. 10 Therefore, NO plays an important role in the regulation of blood P a g e 4 o f 2 2 pressure 11 Impaired NO bioavailability will result in reduced endothelium-dependent vasorelaxation, eventually leading to hypertension. 12 Vascular oxidative stress increased production of ROS with vascular dysfunction. It leads to imbalance between the activity of endogenous pro-oxidative enzymes e.g. xanthine oxidase and antioxidative enzymes e.g. superoxide dismutase in favor of the former. Increased ROS concentrations reduce the amount of bioactive Endothelium-derived (NO) by chemical inactivation to form toxic per-oxy-nitrite.
Enhanced inactivation and/or reduced synthesis of NO is seen in conjunction with risk factors for cardiovascular disease. Therapeutically, drugs in clinical use such as ACE inhibitors can improve endothelial function. 13 Angiotensin-converting enzyme (ACE) plays a vital role in the regulation of BP via the active form, angiotensin II (Ang II). ACE is mainly located on the surface of the endothelium and epithelium involved in the potent vasoconstriction of blood vessels, subsequently leading to elevation of BP. Ang II also stimulates the release of aldosterone, further increasing blood volume and BP due to water and salt retention. 14 Angiotensin-converting enzyme inhibitors (ACE-I) were developed as therapeutic agents targeted for the treatment of hypertension. Captopril is the prototype of the sulfhydryl-containing ACE inhibitors [15] .
Sulfhydryl angiotensin-converting enzyme inhibitors induce sustained reduction of systemic oxidative stress and improve the nitric oxide pathway in patients with essential hypertension. 16 The effects of antihypertensives like angiotensin converting enzyme (ACE) inhibitor and Ca channel blocker are in part due to antioxidant activity. ACE inhibitors increase NO availability by reducing angiotensin II production and bradykinin degradation. Antihypertensive therapy taking this perspective into account would most likely be effective to prevent complications of hypertension. 17 In 1934, Goldblatt et al. developed a hypertension model through partial constriction of the renal artery in dog. This has led to induction of hypertension model using rats, rabbits, sheep, and cats. 18 When the renal artery is ligated or constricted, Renin-Angiotensin-Aldosterone System (RAAS) is activated.
Angiotensinogen is converted to angiotensin-I (Ang I) in the presence of renin secreted by kidney.
ROS regulate collagen metabolism in a variety of non-cardiac cell types. However, it is not known whether ROS can regulate collagen metabolism in cardiac fibroblasts, which are responsible for collagen synthesis and degradation in the myocardium 19 
Experimental design:
The animals were divided into five groups a. Group I: Six rats were served as a control group receiving 0.5 mL of saline by injection.
b. Group II (Non-treated Hypertensive rats):
Six rats with induced hypertension through clipping of right renal artery did not receive any medications throughout the period of the experiments (8 weeks).
c. Group III (Allopurinol-treated Hypertensive rats):
Six rats with induced hypertension through clipping of right renal artery and treated with therapeutic dose of Allopurinol started when rats' systolic blood pressure reached 150 mmHg 3 weeks postoperative for 8weeks.
d. Group IV (Captopril-treated Hypertensive rats):
Six rats with induced hypertension through clipping of right renal artery and treated with therapeutic dose of Captopril tablets started when rats' systolic blood pressure reached 150 mmHg 3 weeks postoperative for 8weeks.
e. Group V (Allopurinol-Captopril-treated Hypertensive rats):
Six rats with induced hypertension through clipping of right renal artery and treated with therapeutic doses of allopurinol and Captopril started when rats' systolic blood pressure reached 150 mmHg 3 weeks postoperative for 8weeks.
Protocol for right renal artery clipping:
The experimental rats were underwent an operation of renal artery constriction. Under anesthesia with 3% sodium pentobarbital (36 mg/kg intraperitoneal), a median longitudinal incision on abdominal skin was performed, then a ring-shaped silver clip with an inner diameter of 0.30 mm was placed around the root 
Protocol for Allopurinol and Captopril intake:
Allopurinol (Zyloric, 300 mg, GlaxoSmithKline, gsk) and Captopril tablets (Capoten, 25 mg, SmithKline Beecham, Egypt, L.L.C.) were dissolved in drinking water ad libitum. The dose of allopurinol per day was carefully calculated by the daily water intake and body weight was approximately 3 mg/kg/day to avoid possible renal damages due to xanthine calculi formation. The dose of captopril was (60 mg/kg/day) 26 started when rats' systolic blood pressure reached 150 mmHg 3 weeks postoperative for 8weeks.The allopurinol and captopril treatment were started as soon as the rats were chronically hypertensive. 27
Measurement of the blood pressure in rats:
Systolic blood pressure (SBP) was measured using a tail-cuff sphygmomanometer in pharmacology department, faculty of pharmacy, Mansoura University, Egypt. All animals were acclimated for blood pressure measurements 1 week before and weekly intervals after renal artery clip for during the drug treatment for 8 weeks. The mean systolic BP in rats was 110 mm Hg before renal artery constriction. The experimental rats were started to receive allopurinol and captopril when the hypertension becomes chronic, i.e. blood pressure became 150 mm Hg (after 3 postoperative weeks). The experimental rats did not show neither renal failure nor renal failure during our study. 28
Histopathological Immunohistochemical Studies:
At the assigned time of scarification 4 and 8 weeks, the rats were anesthetized by pentobarbital overdose (200mg/kg) inhalation followed by mid-sternal incision followed by obtaining of heart and left kidney where they were placed in 10% formaldehyde. All the specimen were removed and prepared for paraffin blocks in pathology department, faculty of Medicine, Mansoura University, Egypt. Sections were cut with a microtome (Leica RM 2025, Germany) at 5 μ m thicknesses and stained with Hematoxylin and Eosin as a routine histological technique and Masson trichrome for staining of collagen fibers indicator for the degree of fibrosis.
Immunohistochemical Study:
Vascular endothelial growth factor-A (VEGF-A) in the myocardium and renal cortex were detected by immunohistochemistry. Sections were incubated with the polyclonal primary antibody against VEGF-A Slides stained with Masson trichrome and Anti-VEGF-A antibodies were photographed using Olympus® digital camera installed on Olympus® microscope with 1/2 X photo adaptor, using 40 X objective. Four sections from each stain for heart and kidney were used. The result images were analyzed on Intel® Core I3® based computer using Video-Test Morphology® software (Russia) with a specific built-in routine for measurement of the collagen surface areas (Masson trichrome stained areas) and the number of positive anti-VEGF-A antibody cells in myocardium and renal cortex after 4 and 8 weeks according to the planned groups.
Statistical Analysis:
Data from Masson trichrome stained and anti-VEGF-A antibody stained sections from all groups were analyzed using Statistical Package for Social Science software computer program version 17 (SPSS, Inc., Chicago, IL, USA). Quantitative parametric data were presented in mean and standard deviation, while
Quantitative non parametric data (the data with abnormal distribution of Anti-VEGF-A antibody rats' hearts of one month hypertensive with or without treatment stained sections) were presented in median and interqurtile range (IQR). For quantitative parametric data, one way Analysis of variance (ANOVA) and tukey were used for comparison of different groups and student's t-test (Paired) for comparing two related groups while for comparing quantitative non-parametric data, Kruskal Wallis test followed by Mann Whitney comparison were used for comparison of different groups and Wilcoxon signed rank test was used for comparing two related groups. P value less than 0.05 was considered statistically significant.
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After 4 weeks:
The myocardium in Control Group I showed normal regular striations with significant absence of There was high significant number of cells of glomeruli and renal tubules with positive expression of
VEGF-A. (Figs 10, 17& 18) and (Tables 3 & 4).
In histopathological examination of Group II (Non-treated Hypertensive rats), myocardium showed disarray with significant increase in interstitial fibrosis. The renal cortex showed ischemic degenerative changes in glomeruli and renal tubules with significant increase in interstitial fibrosis indicated In Group III (Allopurinol-treated Hypertensive rats), the histopathology of myocardium showed disarray with high significant increase in interstitial fibrosis in comparison to that of the control otherwise it is less than that of group II for the same duration. The renal cortex showed mild ischemic degenerative changes in glomeruli and renal tubules. It showed high significant increase in interstitial fibrosis the same as 
After 8 weeks:
The myocardium and renal cortex in Control Group I for two month showed the same histopathological and immunohistochemical findings as the same group for one month normal architecture with regular striations with significant absence of interstitial fibrosis (Figs 1, 10 In histopathological examination of Group II (Non-treated Hypertensive rats), myocardium and renal cortex showed marked significant increase in interstitial fibrosis in comparison with that of the same group In Captopril-treated Hypertensive rats (Group IV), myocardium showed the most high marked In Group V (Allopurinol-Captopril-treated Hypertensive rats), we studied the combined effects of both allopurinol and captopril. The histopathological examination of both myocardium and renal cortex showed nearly normal architecture as that of the control. They showed the high marked significant reduction in interstitial fibrosis in comparison to that of group IV. The renal cortex showed significant reduction in the surface area of interstitial fibrosis to nearly the half of that of the control group (group I) and the fifth of that Renal changes associated with hypertension were explained by several studies. Mechanical forces associated with hypertension increased ROS production. ROS-induced vasoconstriction results from increased intracellular calcium concentration, thereby contributing to the pathogenesis of hypertension. 34 Other studies explained renal changes by the production of vascular superoxide (NOX) which is derived primarily from NADPH oxidase when stimulated by angiotensin II which is already elevated in hypertension. The activation and production NOX is an important molecular mechanism triggering oxidative injury of podocytes. This may represent an early event initiating glomerulosclerosis and hypertrophy of renal tubular cells. 35 Another explanation is homocysteine, is a molecule may play an important role in the pathogenesis of essential hypertension. 36 Elevated homocysteinemia diminishes the vasodilation, increases oxidative stress, stimulates the proliferation of vascular smooth muscle cells ( VSMC), and alters the elastic properties of the vascular wall. 37 Elevated homocysteine levels could lead to oxidant injury of the endothelium. 38 Hypertension-induced ROS stimulate the induction of VEGF expression in various cell types, such as endothelial cells and smooth muscle cells, whereas VEGF induces endothelial cell migration and proliferation through an increase of intracellular ROS. 39 A number of studies have demonstrated this positive relationship between ROS and angiogenesis. Hydrogen peroxide induces VEGF expression in vascular smooth muscle cells, as well as endothelial cells, and thereby promotes angiogenic responses. 40 We compared between the individual effects of allopurinol in Group III and Captopril in Group IV in order to evaluate the effect of combined administration of allopurinol and captopril in group V.
In Allopurinol-treated Hypertensive rats for one month (Group III), the histopathology of myocardium and renal cortex showed high significant increase in interstitial fibrosis. Non-significant number of the cardiac muscle fibers showed positive expression of VEGF-A, renal cortex still had shown significant decrease in the number of cells with positive expression of VEGF-A. After two month, it showed high significant decrease in the surface area of interstitial fibrosis in myocardium and renal cortex. These results confirmed that the long treatment course of hypertension with allopurinol antagonized the fibrotic effects of hypertension in myocardium and renal cortex. This group showed high significant decrease in the maximum number of the myocardium with positive expression of VEGF-A. The renal cortex still had shown significant decrease in the number of cells with positive expression of VEGF-A. The study of VEGF-A in this group concluded that the allopurinol had a dual effects as it decreased its expression in the myocardium and increased its expression in the renal cortex.
Very High dose of Allopurinol (up to 50 mg/kg/day) acted directly as a scavenger for the free radicals with antioxidant properties as demonstrated in vitro hearts. 41 On the other hand, other researches evidenced that lower doses of allopurinol (sufficient to block XO activity) failed to show antioxidant protection but higher doses did. 42 Another study that used both very high dose of allopurinol (100 mg/day for two weeks) and myocardial infarction inducer isoproterenol (ISO) (at a dose of 50mg/kg twice a week for two weeks) P a g e 1 2 o f 2 2 reveals that allopurinol exerts significant cardio-protective effect against ISO induced myocardial infarction in aged rats. This protective effect could be associated with the enhancement of antioxidant defense system and attenuation of inflammatory cells infiltration in the myocardium. 43 The mechanism of improvement in endothelial function with high dose of allopurinol lies in its ability to profound reduction in vascular oxidative stress and not in urate reduction. 44 The results of other research obtained from non-hyperuricemic obstructed kidney model concluded that increase in Xanthine oxidase (XO) activity itself may play an important role in the progression of tissue fibrosis. An example for Xanthine oxidase (XO) inhibitor (febuxostat), may be a therapeutic tool for treating progressive interstitial fibrosis. 45 Allopurinol exhibited dual effects (angio-preventive and angio-promoting effects) in VEGF gene expression on the experimental inflamed fibro-vascular tissue induced in mice by synthetic subcutaneous implant. The contrasting findings were dependent on the phase in which the treatment was initiated. An angio-preventive effect (same as control / decrease in VEGF level) was observed when treated with allopurinol during acute inflammation, whereas angio-promoting effect (increase in VEGF level) was seen treated with allopurinol during the chronic process (that was initiated 8 days post-implantation). 46 In comparison, early Captopril-treated Hypertensive rats (Group IV), myocardium and renal cortex still showed marked significant reduction in interstitial fibrosis. As in groups I, II & III, the number cardiac muscle fibers with positive expression of VEGF-A was still non-significant. The renal cortex showed significant decrease in the number of cells with positive expression of VEGF-A. Late in this group, myocardium showed the most high marked significant reduction in interstitial fibrosis. This indicated that the captopril had more powerful anti-fibrotic effect than that of allopurinol alone through its direct effects and long course treatment. The renal cortex showed interstitial fibrosis slightly higher than that the control group. These results were homogenous with that of the expression of VEGF-A in both myocardium and renal cortex. This group especially this duration (two month) showed the most highly significant increase in number of cells with positive expression of VEGF-A. This means that the captopril alone improved the angiogenesis of myocardium and renal cortex even with the long course of hypertension. This ment that the captopril prevented the progression of the renal impairment. This indicated that the captopril had protective renovascular effects.
The oxidative stress in patients with essential hypertension was improved by chronic administration of therapeutic doses of the sulfhydryl ACE inhibitor but not with the nonsulfhydryl ACE inhibitor. By these data, authors concluded the protective effect of the sulfhydryl ACE inhibition in retarding vascular dysfunction and atherogenesis that often develops rapidly in hypertensive patients. 47 ACE inhibitors as antioxidant strategy had been prooved through ameliorate vasoconstriction, increase the bioactivity of NO, and can inhibit vascular superoxide production at its source. This is why ACE inhibitors may represent a "magic bullet" against vascular oxidative stress. 48
The ACE inhibitors had dual effects in the process of angiogenesis. They improved neovascularization in the diabetic ischemic leg through activation of bradykinin signaling, whereas it reduced vessel growth in the diabetic retina through inhibition of overacting Ang II pathway. 49 Also, it was observed that the addition of ACE inhibitors to endothelial progenitor cells therapy induced the neovascularization and it reduced the number of apoptotic cardiomyocytes. 50 In Group V Combined Allopurinol-Captopril-treated Hypertensive rats for one month, myocardium and renal cortex showed significant reduction in interstitial fibrosis. The immunohistochemical stained sections, there was non-significant increase in the number of cardiac muscle fibers with positive expression of VEGF-A. The renal cortex still had showed significant decrease in the number of cells with positive expression of VEGF-A. After two month, both myocardium and renal cortex showed nearly normal architecture as that of the control. These results was confirmed by Masson trichrome stained sections in which they showed the high marked significant reduction in interstitial fibrosis in comparison to that of group IV. These indicated that the combination between captopril and allopurinol had the same powerful anti-fibrotic effect as that of captopril alone through their direct effects and long course treatment. But, the renal cortex showed significant reduction in the surface area of interstitial fibrosis to nearly the half of that of the control group (group I) and the fifth of that of Group IV (Allopurinol-treated Hypertensive rats). This is why it is better to subscribe the combination between the allopurinol and captopril than that to subscribe one of them alone because this combination was nephron-protective. Moreover, immunohistochemical stained sections added more evidence for the benefits of this combination. In which, there was significant improvement in the process of angiogenesis.
Animal studies proved that the captopril and allopurinol in combination preserved normal blood pressure and insulin sensitivity and prevented hypertriglyceridemia, hyperuricemia, and hypercholesterolemia. The exploration of potential mechanisms that resulted in a superior effect of combined therapy will be evaluated in future studies. 51 Researches on human concluded that the long term maintenance of captopril and allopurinol can lead Experimentally, long term therapy with the combination between allopurinol and captopril is of high benefit for both myocardium and renal cortex in case of chronic hypertension. As the combination decreases the fibrotic changes associated with hypertension and enhances the process of angiogenesis.
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